TRPV2 can be activated by thermal, oxidative, and pharmacological agents, but these methods may cause collateral tissue damage or toxicity.[11] Ultrasound (US) offers a promising alternative due to its noninvasive nature, deep tissue penetration, and ability to precisely control spatial and temporal stimulation.[12] US can enhance tumor barrier permeability, facilitating drug delivery, and, due to the mechanosensitivity of TRPV2, has the potential to activate TRPV2, further promoting targeted calcium overload in breast cancer cells.[13]. The gene discussed is TRPV2; the disease is breast carcinoma.